Jiangsu Simcere Medical Diagnostics Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Jiangsu Simcere Medical Diagnostics Co., Ltd. - overview
Established
2017
Location
Nanjing, Jiangsu, China
Primary Industry
Biotechnology
About
The company's main product is a SDx MassARRAY MALDI-TOF mass spectrometric detection system based on matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), which can be applied to tumor detection, pharmacogenomics detection, infectious disease detection and genetic disease detection, etc. Besides, the company also operates as a personal testing platform, YOAI MEDICINE, providing services such as cervical cancer screening, vaginitis testing, and venereal disease testing.
Current Investors
Hony Capital, Huatai Zijin Investment, Tenyall
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.simceredx.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.